Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential

About this update from Amgen Inc.

Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and rising investment, it’s vital to utilize analytical tools for strategic decisions and capitalize on evolving market dynamics. Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" directory has been added to ResearchAndMarkets.com's offering. The world of bi- and multispecific drugs is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making. In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 278 new bi/multispecific drugs, over 800 drugs with events, and 8,566 total events spanning 2,120 total drug programs - a clear signal of the accelerating pace and complexity in this space. Introducing the Bi/Multispecific Drugs in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities. The Ultimate Tool for Exploring What Makes This Field So Exciting The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the bi/multispecific field one of the most exciting frontiers in oncology today. 6 Game-Changing Benefits for You With the Bi/Multispecific Drugs in Oncology Analytical Tool, you will: Your Bi/Multispecifics in Oncology Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field. You will have thousands of drugs, targets, companies, clinical trials, deals, and much more at your fingertips. See below for a breakdown of near-real-time coverage. Support & Inspiration at Your Fingertips Leverage expertise as your virtual business development team - ready when you are. The 24/7 support ensures help is always available, while rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work. A Tool That Grows With You Unlike static reports that offer just a snapshot in time, the Analytical Tools provide a full year of online access - complete with nearreal-timee updates, new features, pipeline alerts, and dedicated support. When you're ready to go further, you can seamlessly renew your access or upgrade to the industry-leading full-service platform: 1stOncology - your comprehensive partner in oncology drug development. Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development Coverage Breakdown from your Bi/Multispecific Drugs in Oncology Analytical Tool Competitor Overview Top 5 Drug Developers: Top 5 Nations: Pipeline Deals & Alliances Funding & Investors For more information about this directory visit https://www.researchandmarkets.com/r/bk6rwf About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

View stock analysis, news, and events for Amgen Inc.